Syndax Pharmaceuticals Inc. entered an agreement with the U.S. National Cancer Institute to advance its Entinostat and SNDX-6352 cancer treatments.

The cooperative research and development agreement provides Syndax with the required facilities to conduct preclinical and clinical research of the treatments.

The studies will be led by the National Cancer Institute's chief of the Laboratory of Tumor Immunology and Biology, Jeffrey Schlom, and chief of the Genitourinary Malignancies Branch, James Gulley.

They will evaluate both Entinostat and SNDX-6352 as separate treatments and as a combined therapy for cancer. The drugs will also be evaluated in combination with other therapeutic regimens.